3D Systems (DDD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $112.9M, down 9% year-over-year, mainly due to weak hardware/printer sales, while consumables grew 10% and Healthcare Solutions revenue rose 5%, led by Dental and Personalized Healthcare.

• Application Innovation Group revenue increased over 26% year-to-date, reflecting strong demand in regulated industrial and medical markets.

• Net loss was $178.6M, including a $143.7M asset impairment charge; adjusted EBITDA was -$14.3M, down from $4.7M a year ago.

• Operating expenses were reduced sequentially, aided by restructuring and cost-saving actions, with cash burn significantly reduced and inventory expected to be a source of cash.

• Nearly 40 new materials, software enhancements, and platforms launched since Q3 2023, including FDA-cleared dental and orthopedic solutions.

Financial highlights

• Q3 2024 revenue: $112.9M (down 9% YoY); gross margin: 36.9% (GAAP), 37.6% (non-GAAP), 40.2% (non-GAAP, normalized); net loss: $178.6M; adjusted EBITDA: -$14.3M.

• Operating expenses rose to $222.5M due to impairment; non-GAAP OPEX was $61.4M, down sequentially.

• Cash and equivalents at quarter-end were $190M, with cash burn reduced to $3M for the quarter.

• Total debt stood at $211.7M as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue expected between $440M and $450M, with mid- to high single-digit sequential recovery in H2.

• Non-GAAP gross margin guidance for FY2024 is 38–40%; Q4 OpEx expected below $60M, with sequential improvement in adjusted EBITDA anticipated.

• Management expects significant movement toward profitability in 2025, contingent on improved customer capital spending and continued cost management.

• Price/mix headwinds from lower-priced dental materials and limited printer sales to key dental customers expected to persist through 2024.